RMTI · Rockwell Medical, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 1, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jul 1, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Rockwell Medical reported Q2 2026 net sales of $17.8M, up 11% year-over-year, with gross margin expanding to 18% and $2.1M of operating cash flow, while reiterating full-year guidance of $70–75M in net sales, 18–22% gross margin, and $1–2M adjusted EBITDA.
- + Q2 net sales rose 11% year-over-year to $17.8M on new western U.S. customers and higher existing-customer volumes.
- + Gross profit grew 30% year-over-year and gross margin expanded to 18% from 16% on lower manufacturing costs and higher volume.
- + Generated $2.1M of cash from operations in Q2, lifting cash and investments to $24.8M.
- + New Heritage Dialysis agreement and renewed aQua Dialysis agreement extend recurring revenue base with annual pricing provisions.
- + Net loss narrowed to $1.2M in Q2 from $1.5M a year ago and $1.6M in Q1 2026.
- − First-half 2026 net sales were essentially flat year-over-year at $35.1M vs $35.0M, with growth masked by prior-year DaVita volume.
- − Adjusted EBITDA remained negative at $(0.2)M in Q2, flat year-over-year, signaling profitability goals still distant.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RMTI
this stock
Rockwell Medical, Inc.
|
$32.08M | — | -31.8% | — | 2.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 1, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RMTI | -0.3% | +1.7% | — | -4.2% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +0.8% | +3.5% | — | -3.9% | — |